ABSORB II Randomized Controlled Trial
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 501 participants.
Also called NCT01425281
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 501 participants
- Sponsor
- Registry
-
NCT01425281
-
- Other papers using this trial's data
- Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents
- Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Belgium
- Registry status
- Completed
Technical summary
Registry record NCT01425281. Randomized; single masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2016-07 (actual). Results posted on 2019-09-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ABSORB II Randomized Controlled Trial
- Acronym
- ABSORB II
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
- Intervention (Device)
- Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
- Lead sponsor
- Abbott Medical Devices
Record details
- Record id
cardio:ct-nct01425281- Content hash
dd1b83bfb5e4af802a33f111020a3889891c46b89748f3de77c1de1ed44daeca